You are here: Industry Insights > Alvogen

News List

Aztiq-Innobic consortium to buy Alvogen subsidiary for $475m Pharmaceutical-Technology
November 29, 2021
A consortium led by Icelandic pharmaceutical investment fund Aztiq and Thailand-based life sciences company Innobic has agreed to acquire all shares of Alvogen Emerging Market Holdings (AEMH) from its current stakeholders for $475m.
NATCO gets tentative US FDA approval for Ibrutinib tablets expresspharma
April 12, 2021
NATCO feels that it is eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form of the product at the time of launch.
Pfenex Announces U.S. Commercial Launch of Teriparatide Injection americanpharmaceuticalreview
June 23, 2020
Pfenex announced its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.
Alvogen Inks Agreement with Exeltis contractpharma
June 20, 2019
Acquires a targeted portfolio of 23 prescription and OTC drugs in the field of women’s healthcare.
Alvogen, Business Partners Obtain First European Approvals for Generic Ulipristal 5mg americanpharmaceuticalreview
April 11, 2019
Alvogen, Business Partners Obtain First European Approvals for Generic Ulipristal 5mg.
Celgene survives Alvogen's attempt for inter partes review of Revlimid patent in US firstwordpharma
March 15, 2019
The US Patent Office's Patent Trial and Appeal Board (PTAB) on Thursday rebuffed Alvogen's filing requesting an inter partes review of a patent covering Celgene's Revlimid (lenalidomide).
States say Alvogen lawsuit is part of a 'guerilla' war against the death penalty fiercepharma
August 13, 2018
In a battle over lethal execution drugs manufactured by pharma companies, 15 states have backed Nevada in a case alleging drugmaker Alvogen filed a meritless lawsuit only to delay.....
Alvogen court case causes Nevada Judge to halt execution pharmafile
July 17, 2018
A Nevada Judge has temporarily prevented the use of the sedative midazolam, in the execution of the twice convicted killer Scott Raymond Dozier, following objections from the New Jersey-based multinational Alvogen that stated it does not want its drug use
Prestige Biopharma and Alvogen Announce License and Supply Agreement to Commercialize Prestige´s Trastuzumab Biosimilar (Hervelous™) in Central and Eastern Europe b3cnewswire
July 04, 2018
Prestige BioPharma and Alvogen today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar (HD201; Hervelous™) in Central an
Prestige BioPharma, Alvogen Enter Agreement contractpharma
July 03, 2018
Prestige BioPharma and Alvogen have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar (HD201; Hervelous™) in Central and Eastern Europe.

Previous page 1 2 Next page